详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Potential molecular biomarkers for the diagnosis and prognosis of bladder cancer

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China [2]West China School of Medicine, Sichuan University, Chengdu, China [3]Out-patient Department, West China Hospital, Sichuan University, Chengdu, China [4]Research Core Facility, West China Hospital, Sichuan University, Chengdu, China.

出处：

DOI：

ISSN：

关键词： Bladder cancer Molecular biomarkers Molecular subtyping Diagnosis Prognosis

摘要：

Bladder cancer (BC) is a common malignant tumor of urinary system, which can be divided into muscle-invasive BC (MIBC) and nonmuscle-invasive BC (NMIBC). The number of BC patients has been gradually increasing currently. At present, bladder tumours are diagnosed and followed-up using a combination of cystoscopic examination, cytology and histology. However, the detection of early grade tumors, which is much easier to treat effectively than advanced stage disease, is still insufficient. It frequently recurs and can progress when not expeditiously diagnosed and monitored following initial therapy for NMIBC. Treatment strategies are totally different for different stage diseases. Therefore, it is of great practical significance to study new biomarkers for diagnosis and prognosis. In this review, we summarize the current state of biomarker development in BC diagnosis and prognosis prediction. We retrospectively analyse eight diagnostic biomarkers and eight prognostic biomarkers, in which CK, P53, PPARγ, PTEN and ncRNA are emphasized for discussion. Eight molecular subtype systems are also identified. Clinical translation of biomarkers for diagnosis, prognosis, monitoring and treatment will hopefully improve outcomes for patients. These potential biomarkers provide an opportunity to diagnose tumors earlier and with greater accuracy, and help identify those patients most at risk of disease recurrence.Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 2 区

医学

小类 | 1 区药学 2 区医学：研究与实验

最新[2023]版：

大类 | 2 区

医学

小类 | 1 区药学 2 区医学：研究与实验

第一作者：

第一作者机构： [1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China [2]West China School of Medicine, Sichuan University, Chengdu, China

共同第一作者：

通讯作者：

通讯机构： [1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China [*1]Department of Urology, West China Hospital, Sichuan University, No. 37, Guoxue Alley, Chengdu, Sichuan 610041, PR China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Molecular subtyping reveals uniqueness of prognosis in breast ductal carcinoma in situ patients with lumpectomy. [2]Molecular diagnosis and treatment of meningiomas: an expert consensus (2022) [3]Does repeat transurethral resection of bladder tumor influence the diagnosis and prognosis of T1 bladder cancer? A systematic review and meta-analysis. [4]Micropapillary bladder cancer: a clinico-pathological characterization and treatment analysis [5]Overexpression of PTK6 predicts poor prognosis in bladder cancer patients [6]Metabolism-Based Molecular Subtyping Endows Effective Ketogenic Therapy in p53-Mutant Colon Cancer [7]Nanomedicine for urologic cancers: diagnosis and management. [8]Micropapillary bladder cancer: a clinico-pathological characterization and treatment analysis [9]Development and validation of a nomogram for predicting suicide risk and prognostic factors in bladder cancer patients following diagnosis: A population-based retrospective study [10]HMGN5 expression in bladder cancer tissue and its role on prognosis.